interstitial pneumonia and 1 anxiety attack that forced a change in treatment) and 5 with the use of tofacitinib (1 herpes zoster, 1 dry lip, 1 tinnitus, 1 oedema and 1 dyslipidaemia). Of the 21 patients with baricitinib, 4 changed treatment due to ineffectiveness (2 to tofacitinib and 2 to biologics), and of the 11 treated with tofacitinib 2 switched to biologics and 1 suspended treatment due to cardiovascular risk. Conclusion and relevanceIn our clinical experience, baricitinib and tofacitinib are shown to be effective in the treatment of RA, with a good safety profile.

No abstract

No abstract